Acute Aortic Disease.. - Index of

Long-Term Suppressive Therapy 323
18. Van den Steen PE, Proost P, Wuyts A, et al. Neutrophil gelatinase B potentiates
interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III,
PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. Blood 2000; 96(8):
2673–2681.
19. McMillan WD, Patterson BK, Keen RR, et al. In situ localization and quantification
of mRNA for 92-kD type IV collagenase and its inhibitor in aneurysmal, occlusive,
and normal aorta. Arterioscler Thromb Vasc Biol 1995; 15(8):1139–1144.
20. Ogata Y, Enghild JJ, Nagase H. Matrix metalloproteinase-3 (stromelysin) activates the
precursor for the human matrix metalloproteinase-9. J Biol Chem 1992; 267(6):
3581–3584.
21. Bunton TE, Biery NJ, Myers L, et al. Phenotypic alteration of vascular smooth
muscle cells precedes elastolysis in a mouse model of Marfan syndrome. Circ Res
2001; 88(1):37–43.
22. Pyo R, Lee JK, Shipley JM, et al. Targeted gene disruption of matrix metalloproteinase-9
(gelatinase B) suppresses development of experimental abdominal aortic
aneurysms. J Clin Invest 2000; 105(11):1641–1649.
23. Longo GM, Xiong W, Greiner TC, et al. Matrix metalloproteinases-2 and 9 work in
concert to produce aortic aneurysms. J Clin Invest 2002; 110(5):625–632.
24. Holmes DR, Petrinec D, Wester W, et al. Indomethacin prevents elastase-induced
abdominal aortic aneurysms in the rat. J Surg Res 1996; 63(1):305–309.
25. Boyle JR, McDermott E, Crowther M, et al. Doxycycline inhibits elastin degradation
and reduces metalloproteinase activity in a model of aneurysmal disease. J Vasc Surg
1998; 27(2):354–361.
26. Manning MW, Cassis LA, Daugherty A. Differential effects of doxycycline, a broadspectrum
matrix metalloproteinase inhibitor, on angiotensin II-induced atherosclerosis
and abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2003; 23(3):
483–488.
27. Silence J, Lupu F, Collen D, Lijnen HR. Persistence of atherosclerotic plaque but
reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation.
Arterioscler Thromb Vasc Biol 2001; 21(9):1440–1445.
28. Silence J, Collen D, Lijnen HR. Reduced atherosclerotic plaque but enhanced
aneurysm formation in mice with inactivation of the tissue inhibitor of metalloproteinase-1
(TIMP-1) gene. Circ Res 2002; 90(8):897–903.
29. Mao D, Lee JK, VanVickle SJ, Thompson RW. Expression of collagenase-3 (MMP-13)
in human abdominal aortic aneurysms and vascular smooth muscle cells in culture.
Biochem Biophys Res Commun 1999; 261(3):904–910.
30. Nataatmadja M, West M, West J, et al. Abnormal extracellular matrix protein transport
associated with increased apoptosis of vascular smooth muscle cells in marfan syndrome
and bicuspid aortic valve thoracic aortic aneurysm. Circulation 2003; 108(suppl 1):
II329–II334.
31. Segura AM, Luna RE, Horiba K, et al. Immunohistochemistry of matrix metalloproteinases
and their inhibitors in thoracic aortic aneurysms and aortic valves of
patients with Marfan‘s syndrome. Circulation 1998; 98(19 suppl):II331–337,
discussion II337–II338.
32. Boyum J, Fellinger EK, Schmoker JD, et al. Matrix metalloproteinase activity in
thoracic aortic aneurysms associated with bicuspid and tricuspid aortic valves.
J Thorac Cardiovasc Surg 2004; 127(3):686–691.
33. LeMaire SA, Wang X, Wilks JA, et al. Matrix metalloproteinases in ascending aortic
aneurysms: bicuspid versus trileaflet aortic valves. J Surg Res 2005; 123(1):40–48.